FDA Brief

Warning letters Drugs

FDA warning letter to

Wizcure Pharmaa Private Limited

High riskIssued Jun 24Posted Jun 30Center for Drug Evaluation and Research (CDER)

FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.

What happened

FDA inspected the Bhiwadi, Rajasthan facility from December 3 to 10, 2025. Investigators found laboratory records did not include complete original data: microbial plates showing growth were discarded and replaced with no-growth plates, and required environmental and personnel monitoring samples were missed. They also found the aseptic filling line lacked a physical barrier, product-contact equipment was not sterilized, equipment was rusty, and media fills and airflow studies were inadequate.

What FDA found

  1. Laboratory records did not include complete original data; microbial plates with visible growth were thrown away and replaced with plates showing no growth, and required monitoring samples were missed.

    21 CFR 211.194(a)
  2. The aseptic filling line had no physical barrier between the ISO 5 filling zone and the ISO 7 room, product-contact equipment was not sterilized, and the room lacked adequate space for people and materials.

    21 CFR 211.42(c)(10)
  3. Media fills did not represent commercial aseptic operations, batch records did not document all personnel and interventions, smoke studies were not done under dynamic conditions, and aseptic operator practices deviated.

    21 CFR 211.113(b)
  4. The filling line and air filters above it had rust or stains, and equipment was not adequately cleaned and maintained for sterile manufacturing.

    21 CFR 211.67(a)

What FDA wants

FDA asks Wizcure to provide independent assessments and detailed remediation and CAPA plans covering laboratory data integrity, aseptic facilities and contamination controls, environmental monitoring, media fills, airflow, equipment, the quality unit, and related systems. FDA also asks the firm to clarify whether it will resume U.S. manufacturing and to notify FDA before resuming; the letter does not state a response deadline.

Who should pay attention

  • companies that buy or distribute Wizcure sterile OTC drugs
  • sterile drug manufacturers and contract manufacturers that rely on microbial monitoring
  • quality and regulatory teams responsible for U.S. marketed sterile products

This is a summary. Read the original letter on fda.gov.

Wizcure Pharmaa Private Limited's FDA history

Recalls in the last 12 months

Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
BioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 - Samrudhhi, Opp. Sakar-III, Navrangpura, Ahmedabad, Gujarat, India - 380014, Email:info@omnilens.in, Manufac…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
Bio Glo Fluorescein Sodium Ophthalmic Strips USP, 300 diagnostic strips, Manufactured Omni Lens Pvt Ltd 5 - Samruddhi, Opp. Sakar - III, Navrangpura, Ahmedabad - 380014, India, Email:info@omnilens.in, Manufactured for &…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
Vista Tears Polyethylene Glycol 400 0.4% w/v, Propylene Glycol 0.3% w/v Eye Drops, Dry Eye Relief, Lubricant Drops, Sterile 10 ml (1/3 fl. oz.), Manufactured by: RA/Drugs/ MFG/2019/196283, Omni Lens Pvt. Ltd. 5, Samrudhh…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
Vista Gel Hypromellose USP 0.3% w/v, Eye Drops Dry Eye Relief Lubricating Gel, 10 ml. (1/3 fl. oz), Wizcure Pharmaa PVT. LTD, H-881, Phase-3, RIICO Industrial Area, Bhiwadi-301019, India, Manufactured for and distributed…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
Vista Gonio Eye Lubricant, Hypromellose Ophthalmic Solution USP (Sterile Drops. Dry Eye Relief, 15 ml. (1/2 fl. oz.), Wizcure Pharmaa Pvt. Ltd., H-881, Phase-3, RIICO Industrial Area, Bhiwadi-901019, INDIA, Manufactured …
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
Vista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula, 10 ml (1/3 fl.oz.), Wizcure Pharmaa PVT. LTD., H-881, Phase 3, RIICO Industrial Area, Bhiwadi-301019, India, Manufacture…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Mar 4 Class II Wizcure Pharmaa Private Limited
Drug
CHNaO Fluorescein Sodium Ophthalmic Strips, USP 1mg, packaged as a) 100-count box, NDC 83851-100-10; b) 300-count box, NDC 83851-100-30. Manufactured by Wizcure Pharmaa PVT. LTD, H-681, Phase 3, RIICO Industrial Area, B…
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk